Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences

• GDT002 shown to have a potent anti-tumor activity across a broad spectrum of solid and liquid tumors
• Ovarian cancer selected from broad screening of solid tumor types as the indication for GDT002

Utrecht, Netherlands and Boston, Mass., 28 March 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every cancer patient, is pleased to announce that Chief Executive Officer Marcel Zwaal and Chief Scientific Officer Mark Throsby will be presenting data on γδ TCR-based immunotherapies for solid tumors at the following upcoming scientific conferences:

Innate Natural Killer Summit 2022

Date: 30 March -1 April, San Diego, CA

Panel: “Developing commercial strategy for allogeneic therapies”

Participant: Marcel Zwaal

Date & Time: 1 April, 13.30pm – 14.15pm CST

Presentation: “Leveraging Innate Immune Pathways with T cell Therapies to Elicit Stronger, safer Responses”

Presenter: Marcel Zwaal

Date & Time: 1 April, 14.45pm – 15.15pm CST

American Association for Cancer Research (AACR) Annual Meeting 2022

Date: 8 April -13 April, New Orleans, Louisiana

Presentation title: Targeting solid tumors with GDT002, a first-in-class γδTCR-based T cell therapy

Section: 35

Presenter/Authors: Esther Drent, Andrea Bisso, Sjoerd Baardman, Dagmar Verweij, Estefania Salcedo, Chris Coomans, Steven Braem, Sander Van de Weg, Sara Melief, Haakan Norell, Marleen Van Loenen, Stefania Gobessi, Mark Throsby.

Date & Time: 24 April, 09.00am – 12.30pm CST

Marcel Zwaal, Chief Executive Officer of Gadeta, said: “I look forward to presenting data at these prestigious conferences to showcase Gadeta’s progress in discovering innovative, gamma delta TCR-based immunotherapies as well as developing our groundbreaking TEG platform. Our promising pipeline is creating a new universe of tumor targeting agents and is advancing through clinical development at pace with our lead candidate, GDT002 about to enter Phase 1/2 trials in a solid tumor indication and GDT201 undergoing IND-enabling clinical studies for colorectal cancer.”

Mark Throsby, Co-author of the study and Chief Scientific Officer of Gadeta, added: “Broad application of cell therapies like CAR-T have been hampered by a lack of tumor-specific targets. Gadeta leverages the natural HLA-independent tumor recognition capabilities of γδTCRs combined with the proliferative capacity and robust tumor killing of αβT cells to develop tumor-specific cell therapies. We look forward to presenting to the scientific community our results which demonstrate that GDT002 has a potent anti-tumor activity across a broad spectrum of solid and liquid tumor types as well as to discuss the data behind our decision to select ovarian cancer as an indication to explore the clinical effect of GDT002 against solid tumors.”

If you would like to meet with Gadeta’s management team at any of the above events, please contact us at the details provided below. For more information, please visit us at https://www.gadeta.nl/.